Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies.
The purpose of this review is to examine the biologic, pharmacologic, and clinical differences between the three currently approved phosphodiesterase-5 inhibitors to help the clinician make an educated choice about which medication may be best for any individual patient.
McCullough
Andrew
A
New York University School of Medicine, 150 East 32nd Street, Second Floor, New York, NY 10016, USA. andy.mccullough@nyumc.org
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D002243:Carbolines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism*; D010879:Piperazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D000068581:Tadalafil; D014227:Triazines; D000069058:Vardenafil Dihydrochloride
D002243:Carbolines; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride; D000068581:Tadalafil; D000068677:Sildenafil Citrate; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human